Increased dosage of carbidopa in parkinsonian patients on low carbidopa-levodopa regimen. Effect of levodopa bioavailability

M. Contin, R. Riva, P. Martinelli, G. Procaccianti, A. Baruzzi

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

The effect of a 2.5-fold increase in daily carbidopa intake on the bioavailability of levodopa was studied in six patients with Parkinson's disease on a low chronic regimen of carbidopa-levodopa (Sinemet) at the fixed ratio of 1:10. The extent of levodopa absorption, expressed as the area under the 11-h plasma levodopa concentration-time curve (AUC(0-11 h)), was not enhanced by the higher carbidopa dose. A significant increase in the AUC was found for the levodopa metabolite 3-O-methyldopa at the higher carbidopa intake. Clinical performances of individual patients were identical with both carbidopa-levodopa ratios. From these data, an adequate inhibition of peripheral decarboxylation and hence a good bioavailability of levodopa may be expected in patients taking low doses of carbidopa-levodopa, using currently available commercial preparations.

Original languageEnglish
Pages (from-to)75-81
Number of pages7
JournalClinical Neuropharmacology
Volume12
Issue number1
Publication statusPublished - 1989

Fingerprint

Carbidopa
Levodopa
Biological Availability
Area Under Curve
Decarboxylation
Parkinson Disease
levodopa drug combination carbidopa

ASJC Scopus subject areas

  • Clinical Neurology
  • Pharmacology (medical)
  • Neuroscience(all)
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

@article{5e6c6f011ac846f6a5067567cf85c5d9,
title = "Increased dosage of carbidopa in parkinsonian patients on low carbidopa-levodopa regimen. Effect of levodopa bioavailability",
abstract = "The effect of a 2.5-fold increase in daily carbidopa intake on the bioavailability of levodopa was studied in six patients with Parkinson's disease on a low chronic regimen of carbidopa-levodopa (Sinemet) at the fixed ratio of 1:10. The extent of levodopa absorption, expressed as the area under the 11-h plasma levodopa concentration-time curve (AUC(0-11 h)), was not enhanced by the higher carbidopa dose. A significant increase in the AUC was found for the levodopa metabolite 3-O-methyldopa at the higher carbidopa intake. Clinical performances of individual patients were identical with both carbidopa-levodopa ratios. From these data, an adequate inhibition of peripheral decarboxylation and hence a good bioavailability of levodopa may be expected in patients taking low doses of carbidopa-levodopa, using currently available commercial preparations.",
author = "M. Contin and R. Riva and P. Martinelli and G. Procaccianti and A. Baruzzi",
year = "1989",
language = "English",
volume = "12",
pages = "75--81",
journal = "Clinical Neuropharmacology",
issn = "0362-5664",
publisher = "Lippincott Williams and Wilkins",
number = "1",

}

TY - JOUR

T1 - Increased dosage of carbidopa in parkinsonian patients on low carbidopa-levodopa regimen. Effect of levodopa bioavailability

AU - Contin, M.

AU - Riva, R.

AU - Martinelli, P.

AU - Procaccianti, G.

AU - Baruzzi, A.

PY - 1989

Y1 - 1989

N2 - The effect of a 2.5-fold increase in daily carbidopa intake on the bioavailability of levodopa was studied in six patients with Parkinson's disease on a low chronic regimen of carbidopa-levodopa (Sinemet) at the fixed ratio of 1:10. The extent of levodopa absorption, expressed as the area under the 11-h plasma levodopa concentration-time curve (AUC(0-11 h)), was not enhanced by the higher carbidopa dose. A significant increase in the AUC was found for the levodopa metabolite 3-O-methyldopa at the higher carbidopa intake. Clinical performances of individual patients were identical with both carbidopa-levodopa ratios. From these data, an adequate inhibition of peripheral decarboxylation and hence a good bioavailability of levodopa may be expected in patients taking low doses of carbidopa-levodopa, using currently available commercial preparations.

AB - The effect of a 2.5-fold increase in daily carbidopa intake on the bioavailability of levodopa was studied in six patients with Parkinson's disease on a low chronic regimen of carbidopa-levodopa (Sinemet) at the fixed ratio of 1:10. The extent of levodopa absorption, expressed as the area under the 11-h plasma levodopa concentration-time curve (AUC(0-11 h)), was not enhanced by the higher carbidopa dose. A significant increase in the AUC was found for the levodopa metabolite 3-O-methyldopa at the higher carbidopa intake. Clinical performances of individual patients were identical with both carbidopa-levodopa ratios. From these data, an adequate inhibition of peripheral decarboxylation and hence a good bioavailability of levodopa may be expected in patients taking low doses of carbidopa-levodopa, using currently available commercial preparations.

UR - http://www.scopus.com/inward/record.url?scp=0024545857&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0024545857&partnerID=8YFLogxK

M3 - Article

C2 - 2713868

AN - SCOPUS:0024545857

VL - 12

SP - 75

EP - 81

JO - Clinical Neuropharmacology

JF - Clinical Neuropharmacology

SN - 0362-5664

IS - 1

ER -